drugset
Drugs / TQC2731
last change Oct 2025 re-read 3 minutes ago

TQC2731

Monoclonal antibody targets TSLP via inhibition

Developed for
asthma · chronic rhinosinusitis · chronic asthma · chronic obstructive pulmonary disease · nasal cavity polyp
Investigated by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Trials 6

today NCT06829784 · Ph 3 NCT06707883 · Ph 2 NCT06451640 · Ph 2 NCT06036927 · Ph 2 NCT05472324 · Ph 2 NCT04923607 · Ph 1
2022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04923607 Jun 2021 → Aug 2023 chronic asthma Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Unknown No outcome recorded
Phase 24 trials
Phase 2 NCT06707883 Dec 2024 → Dec 2026 expected chronic obstructive pulmonary disease Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Active not recruiting No outcome recorded
Phase 2 NCT06451640 Jul 2024 → Oct 2025 chronic rhinosinusitis Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 2 NCT06036927 Dec 2023 → Feb 2025 chronic rhinosinusitis, nasal cavity polyp Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Completed No outcome recorded
Phase 2 NCT05472324 Sep 2022 → Mar 2025 asthma Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT06829784 Mar 2025 → Dec 2027 expected asthma Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Recruiting No outcome recorded
Comparator or background therapy1 trial
Phase 3 NCT07107256 Comparator Sep 2025 → Mar 2027 expected chronic rhinosinusitis Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as TQC2731 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06451640 ↗
6

NCT06707883 ↗

NCT07107256 ↗

NCT04923607 ↗

NCT05472324 ↗

NCT06829784 ↗

NCT06036927 ↗
Action Inhibit “blocks thymic stromal lymphopoietin (TSLP)” NCT06707883 ↗
Modality Monoclonal antibody “TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.” NCT05472324 ↗
Route Subcutaneous “subcutaneous(sc.) injection of TQC2731(12mg、105mg、210mg、420mg、630mg) once” NCT04923607 ↗
Target TSLP “TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.” NCT06451640 ↗